LONDON — Abivax on Monday night disclosed additional data for its experimental ulcerative colitis drug, seemingly allaying at least some of the safety concerns that had flared in recent weeks.
U.S.-listed shares of the French firm were up some 25% overnight into Tuesday morning.
Earlier this month, Abivax reported that the drug, called obefazimod, delivered strong efficacy in a closely watched maintenance trial, with far more participants on the study drug entering a period of no symptoms of their bowel disease versus those on placebo. But a number of cancer cases among people on obefazimod raised questions about potential safety risks, with company shares plummeting in response.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.